# HBV Reactivation in Immunocompromised Patients (REANT STUDY)

> **NCT07529171** · — · RECRUITING · sponsor: **Yaşar Bayındır, MD** · enrollment: 490 (estimated)

## Conditions studied

- HBV

## Interventions

- **DRUG:** Antiviral

## Key facts

- **NCT ID:** NCT07529171
- **Lead sponsor:** Yaşar Bayındır, MD
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-09
- **Primary completion:** 2026-06-30
- **Final completion:** 2029-12-31
- **Target enrollment:** 490 (ESTIMATED)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07529171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07529171, "HBV Reactivation in Immunocompromised Patients (REANT STUDY)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07529171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*